Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag BioVaxys converted $25K in debt plus interest into 148,468 shares and granted 550K stock options to insiders.

flag BioVaxys Technology Corp. converted $25,000 in convertible debentures plus $239.73 in accrued interest into 148,468 common shares at $0.17 per share after a holder’s notice. flag The company also granted 550,000 stock options to insiders and key personnel, exercisable at $0.25 per share until October 20, 2030, with gradual vesting. flag The transactions were exempt from certain Canadian regulations due to limited insider involvement. flag The firm, based in British Columbia, develops immunotherapies for cancer, infectious diseases, and allergies using its DPX™ and HapTenix© platforms. flag Its lead candidate, maveropepimut-S, is in Phase IIb trials for advanced lymphoma and ovarian cancer, demonstrating safety and immune response. flag Other pipeline projects include dual-targeted therapies, peanut allergy treatments, and personalized cancer vaccines. flag All securities are subject to regulatory approval and are not registered for sale in the U.S.

3 Articles